The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation

Brain vascular inflammation is characterized by endothelial activation and immune cell recruitment to the blood vessel wall, potentially causing a breach in the blood - brain barrier, brain parenchyma inflammation, and a decline of cognitive function. The clinical-stage small molecule, apabetalone, reduces circulating vascular endothelial inflammation markers and improves cognitive scores in elderly patients by targeting epigenetic regulators of gene transcription, bromodomain and extraterminal proteins. However, the effect of apabetalone on cytokine-activated brain vascular endothelial cells (BMVECs) is unknown. Here, we show that apabetalone treatment of BMVECs reduces hallmarks of

Informations de copyright

© 2023 the author(s), published by De Gruyter.

Déclaration de conflit d'intérêts

Conflict of interest: S.W., L.F, E.D., D.G., B.D.R., S.C.S, L.M.T., C.D.S., R.J., J.O.J., M.S., N.C.W.W., and E.K. were employed by Resverlogix Corp. at the time of the study and hold company’s shares and stock options. All other authors state no conflict of interest.